Stock 3320 CHINA RESOURCES PHARMACEUTICAL GROUP LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials China Resources Pharmaceutical Group Limited

Equities

3320

HK0000311099

Pharmaceuticals

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:08 2024-06-04 am EDT 		5-day change 1st Jan Change
5.75 HKD +2.49% Intraday chart for China Resources Pharmaceutical Group Limited -5.58% +12.09%
May. 30 China Resources Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2023 CI
May. 16 China Resources Sanjiu, China Resources Power to Continue Cooperating on New Energy Projects MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 45,437 25,004 22,303 39,705 32,229 36,313 - -
Enterprise Value (EV) 1 74,178 57,928 61,337 73,426 71,468 69,381 67,907 62,874
P/E ratio 13.9 x 7.65 x 5.92 x 9.58 x 7.76 x 7.87 x 6.99 x 6.5 x
Yield 1.52% 3.02% 4.23% 2.53% 3.25% 2.9% 3.25% 3.41%
Capitalization / Revenue 0.22 x 0.12 x 0.09 x 0.16 x 0.12 x 0.13 x 0.11 x 0.1 x
EV / Revenue 0.36 x 0.29 x 0.26 x 0.29 x 0.27 x 0.24 x 0.21 x 0.18 x
EV / EBITDA 5.9 x 4.91 x 4.83 x 4.38 x 4.65 x 4.22 x 3.73 x 3.21 x
EV / FCF 11.3 x 8.86 x 5.88 x 7.47 x - 13.4 x 9.24 x 6.93 x
FCF Yield 8.82% 11.3% 17% 13.4% - 7.44% 10.8% 14.4%
Price to Book 1.12 x 0.54 x 0.44 x 0.8 x 0.32 x 0.68 x 0.61 x 0.56 x
Nbr of stocks (in thousands) 6,284,506 6,282,510 6,282,510 6,282,510 6,282,510 6,282,510 - -
Reference price 2 7.230 3.980 3.550 6.320 5.130 5.780 5.780 5.780
Announcement Date 3/30/20 3/26/21 3/29/22 3/30/23 3/26/24 - - -
1HKD in Million2HKD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 204,454 200,423 236,806 254,106 265,229 289,142 320,396 351,134
EBITDA 1 12,576 11,790 12,690 16,775 15,382 16,443 18,227 19,596
EBIT 1 10,212 9,346 9,868 13,623 11,952 13,908 15,256 16,534
Operating Margin 4.99% 4.66% 4.17% 5.36% 4.51% 4.81% 4.76% 4.71%
Earnings before Tax (EBT) 1 6,640 7,076 8,408 9,856 10,709 11,914 13,308 14,672
Net income 1 3,286 3,297 3,769 4,147 4,178 4,673 5,230 5,602
Net margin 1.61% 1.65% 1.59% 1.63% 1.58% 1.62% 1.63% 1.6%
EPS 2 0.5200 0.5200 0.6000 0.6600 0.6612 0.7341 0.8264 0.8891
Free Cash Flow 1 6,544 6,537 10,428 9,833 - 5,164 7,353 9,075
FCF margin 3.2% 3.26% 4.4% 3.87% - 1.79% 2.29% 2.58%
FCF Conversion (EBITDA) 52.04% 55.45% 82.17% 58.62% - 31.41% 40.34% 46.31%
FCF Conversion (Net income) 199.13% 198.27% 276.68% 237.09% - 110.51% 140.59% 162%
Dividend per Share 2 0.1100 0.1200 0.1500 0.1600 0.1669 0.1679 0.1881 0.1968
Announcement Date 3/30/20 3/26/21 3/29/22 3/30/23 3/26/24 - - -
1HKD in Million2HKD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S2 2020 S1 2020 S2 2021 S1 2021 S2 2022 S1 2022 S2 2023 S1 2023 S2 2024 S1 2024 S2 2025 S1 2025 S2
Net sales 1 102,531 89,387 111,036 114,488 122,319 125,716 128,390 138,940 114,635 143,963 128,572 160,464 143,838
EBITDA - - 4,573 - - - - - - - - - -
EBIT 1 - - 3,711 6,481 4,058 7,822 5,801 7,745 3,557 8,513 5,269 9,761 5,277
Operating Margin - - 3.34% 5.66% 3.32% 6.22% 4.52% 5.57% 3.1% 5.91% 4.1% 6.08% 3.67%
Earnings before Tax (EBT) - - 2,586 - - - - 7,117 2,995 - - - -
Net income - - 719.9 - - - - 3,038 884.6 - - - -
Net margin - - 0.65% - - - - 2.19% 0.77% - - - -
EPS 2 0.0400 0.4100 0.1100 0.3900 0.2100 0.4800 0.1800 - 0.1409 0.4900 0.2100 0.5600 0.1900
Dividend per Share - - - - - - - - - - - - -
Announcement Date 3/30/20 8/27/20 3/26/21 8/25/21 3/29/22 8/25/22 3/30/23 8/31/23 3/26/24 - - - -
1HKD in Million2HKD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 28,741 32,924 39,035 33,720 39,238 33,068 31,594 26,561
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 2.285 x 2.792 x 3.076 x 2.01 x 2.551 x 2.011 x 1.733 x 1.355 x
Free Cash Flow 1 6,544 6,537 10,428 9,833 - 5,164 7,353 9,075
ROE (net income / shareholders' equity) 8.21% 7.56% 7.73% 8.25% 8.61% 8.48% 8.79% 8.44%
ROA (Net income/ Total Assets) 1.8% 1.65% 1.65% 1.69% 1.67% 2.21% 2.3% 2.2%
Assets 1 183,087 199,693 228,973 244,931 250,540 211,441 227,581 254,769
Book Value Per Share 2 6.480 7.400 8.110 7.890 16.00 8.530 9.490 10.40
Cash Flow per Share 2 1.910 2.140 2.040 5.140 - 2.090 1.330 1.340
Capex 1 1,597 1,669 2,415 2,798 - 3,563 3,815 3,787
Capex / Sales 0.78% 0.83% 1.02% 1.1% - 1.23% 1.19% 1.08%
Announcement Date 3/30/20 3/26/21 3/29/22 3/30/23 3/26/24 - - -
1HKD in Million2HKD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for China Resources Pharmaceutical Group Limited

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
5.78 HKD
Average target price
7.382 HKD
Spread / Average Target
+27.72%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
CHINA RESOURCES PHARMACEUTICAL GROUP LIMITED Stock China Resources Pharmaceutical Group Limited
+12.09% 4.64B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+42.60% 748B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+33.06% 598B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.74% 356B
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.79% 325B
ABBVIE INC. Stock AbbVie Inc.
+3.37% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+17.02% 245B
NOVARTIS AG Stock Novartis AG
+8.66% 211B
ROCHE HOLDING AG Stock Roche Holding AG
-4.34% 209B
AMGEN INC. Stock Amgen Inc.
+6.74% 165B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 3320 Stock
  4. Financials China Resources Pharmaceutical Group Limited